Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dual Antithrombotc Therapy-The First Affiliated Hospital with Nanjing Medical University-acute coronary syndrome-atrial fibrillation
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dual antithrombotic therapy (DAT) as defined in the OPTIMA-4 sub-study (sponsored by The First Affiliated Hospital with Nanjing Medical University) consists of the direct oral anticoagulant dabigatran etexilate combined with a P2Y12 inhibitor (either clopidogrel or ticagrelor). This combination is specifically investigated for patients with acute coronary syndrome (ACS) and non-valvular atrial fibrillation (NVAF) who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents. Dabigatran acts as a direct thrombin inhibitor, while clopidogrel and ticagrelor inhibit platelet aggregation by antagonizing the P2Y12 receptor. The regimen aims to provide sufficient anticoagulation and antiplatelet effects to prevent stroke and stent thrombosis while minimizing the bleeding risks associated with triple antithrombotic therapy (which includes aspirin).
- Other names
- Dual Antithrombotic Therapydabigatran + clopidogreldabigatran + ticagrelor
02
Targets
F2 (Thrombin)P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on Dual Antithrombotc Therapy-The First Affiliated Hospital with Nanjing Medical University-acute coronary syndrome-atrial fibrillation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual Antithrombotc Therapy-The First Affiliated Hospital with Nanjing Medical University-acute coronary syndrome-atrial fibrillation.